BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1133 related articles for article (PubMed ID: 19080333)

  • 21. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
    Zhang F; Lee J; Lu S; Pettaway CA; Dong Z
    Clin Cancer Res; 2005 Jun; 11(12):4512-20. PubMed ID: 15958637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model.
    Terada N; Shimizu Y; Kamba T; Inoue T; Maeno A; Kobayashi T; Nakamura E; Kamoto T; Kanaji T; Maruyama T; Mikami Y; Toda Y; Matsuoka T; Okuno Y; Tsujimoto G; Narumiya S; Ogawa O
    Cancer Res; 2010 Feb; 70(4):1606-15. PubMed ID: 20145136
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice.
    Sato N; Gleave ME; Bruchovsky N; Rennie PS; Beraldi E; Sullivan LD
    Cancer Res; 1997 Apr; 57(8):1584-9. PubMed ID: 9108464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Androgen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers.
    Ko YJ; Devi GR; London CA; Kayas A; Reddy MT; Iversen PL; Bubley GJ; Balk SP
    J Urol; 2004 Sep; 172(3):1140-4. PubMed ID: 15311058
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Zanthoxyli Fructus induces growth arrest and apoptosis of LNCaP human prostate cancer cells in vitro and in vivo in association with blockade of the AKT and AR signal pathways.
    Yang Y; Ikezoe T; Takeuchi T; Adachi Y; Ohtsuki Y; Koeffler HP; Taguchi H
    Oncol Rep; 2006 Jun; 15(6):1581-90. PubMed ID: 16685399
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro and in vivo anticancer effects of the novel vitamin E ether analogue RRR-alpha-tocopheryloxybutyl sulfonic acid in prostate cancer.
    Ni J; Mai T; Pang ST; Haque I; Huang K; DiMaggio MA; Xie S; James NS; Kasi D; Chemler SR; Yeh S
    Clin Cancer Res; 2009 Feb; 15(3):898-906. PubMed ID: 19188160
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Suppression of androgen receptor expression by dibenzoylmethane as a therapeutic objective in advanced prostate cancer.
    Jackson KM; Frazier MC; Harris WB
    Anticancer Res; 2007; 27(3B):1483-8. PubMed ID: 17595765
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Curcumin blocks the activation of androgen and interlukin-6 on prostate-specific antigen expression in human prostatic carcinoma cells.
    Tsui KH; Feng TH; Lin CM; Chang PL; Juang HH
    J Androl; 2008; 29(6):661-8. PubMed ID: 18676361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
    Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
    Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors.
    Gleave ME; Hsieh JT; Wu HC; von Eschenbach AC; Chung LW
    Cancer Res; 1992 Mar; 52(6):1598-605. PubMed ID: 1371718
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis.
    Matsubara S; Wada Y; Gardner TA; Egawa M; Park MS; Hsieh CL; Zhau HE; Kao C; Kamidono S; Gillenwater JY; Chung LW
    Cancer Res; 2001 Aug; 61(16):6012-9. PubMed ID: 11507044
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phytoestrogens from Belamcanda chinensis regulate the expression of steroid receptors and related cofactors in LNCaP prostate cancer cells.
    Thelen P; Peter T; Hünermund A; Kaulfuss S; Seidlová-Wuttke D; Wuttke W; Ringert RH; Seseke F
    BJU Int; 2007 Jul; 100(1):199-203. PubMed ID: 17488304
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis.
    Rocchi P; Beraldi E; Ettinger S; Fazli L; Vessella RL; Nelson C; Gleave M
    Cancer Res; 2005 Dec; 65(23):11083-93. PubMed ID: 16322258
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo.
    Xia Q; Sung J; Chowdhury W; Chen CL; Höti N; Shabbeer S; Carducci M; Rodriguez R
    Cancer Res; 2006 Jul; 66(14):7237-44. PubMed ID: 16849572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of a transplantable hormone-responsive human prostatic cancer xenograft TEN12 and its androgen-resistant sublines.
    Harper ME; Goddard L; Smith C; Nicholson RI
    Prostate; 2004 Jan; 58(1):13-22. PubMed ID: 14673948
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A molecular mimic of phosphorylated prolactin markedly reduced tumor incidence and size when DU145 human prostate cancer cells were grown in nude mice.
    Xu X; Kreye E; Kuo CB; Walker AM
    Cancer Res; 2001 Aug; 61(16):6098-104. PubMed ID: 11507059
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
    Koochekpour S; Lee TJ; Wang R; Culig Z; Delorme N; Caffey S; Marrero L; Aguirre J
    Prostate; 2007 Feb; 67(2):178-89. PubMed ID: 17044040
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical antitumor activity of the oral platinum analog satraplatin.
    Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo.
    Dorai T; Cao YC; Dorai B; Buttyan R; Katz AE
    Prostate; 2001 Jun; 47(4):293-303. PubMed ID: 11398177
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Suppression of prostate tumor cell growth in vivo by WT1, the Wilms' tumor suppressor gene.
    Fraizer G; Leahy R; Priyadarshini S; Graham K; Delacerda J; Diaz M
    Int J Oncol; 2004 Mar; 24(3):461-71. PubMed ID: 14767530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 57.